Merck and Japan-based Eisai said on Friday a combination of their therapies failed to extend the lives of patients with a ...

The FDA has approved the sBLA of Eisai and Biogen's LEQEMBI for maintenance dosing indicated for the early stages of ...

The U.S. Food and Drug Administration has approved monthly maintenance dosing for Japan's Eisai and partner Biogen's ...

The European medicines regulator said on Friday it will review safety information for Eisai and Biogen's Leqembi that the ...

Japanese pharmaceutical company Eisai Co. and U.S. firm Biogen Inc. said Monday that a jointly developed Alzheimer's drug has ...

The monthly maintenance regimen, which offers a more convenient frequency than the initially approved treatment schedule for ...

MSD and Eisai’s trial saw mixed success with its two primary endpoints, seeing success in progression-free survival, but ...

Biogen and Eisai said they believe that EC's requests can be addressed with existing information, and that no new safety signals have been identified for Leqembi. The U.S. Food and Drug Administration ...

Biogen and Eisai have won Food and Drug Administration approval of an intravenous maintenance dosing of their Leqembi drug for early Alzheimer's disease. The companies late Sunday said the FDA ...

The companies report that the safety profile ... with no new safety signals identified after the drug's launch. Eisai’s commitment to rapidly deliver lecanemab to patients in EU countries ...

In the companies’ pivotal clinical trial ... International Conference in Philadelphia aimed at showing that Eisai’s drug continues to benefit patients who stay on Leqembi after amyloid ...

Biogen and Eisai have won Food and Drug Administration approval of an intravenous maintenance dosing of their Leqembi drug for early Alzheimer's disease. The companies late Sunday said the FDA ...